Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis

Sofia Perea, Manuel Hidalgo, Alberto Arcediano, Maria Jose Ramos, Carlos Gomez, Javier Hornedo, Carlos Lumbreras, Dolores Folgueira, Hernan Cortes-Funes, Antonio Rodriguez-Noriega

Research output: Contribution to journalArticle

Abstract

This study evaluated the susceptibility of Escherichia coli to quinolones in 72 stool samples collected from 31 patients with solid tumours who had undergone high dose chemotherapy (HDC) and peripheral blood stem-cell (PBSC) rescue with ciprofloxacin prophylaxis. Samples were obtained at admission, after completing prophylaxis and three months later. All E. coli strains isolated from baseline samples were susceptible to quinolones. Fluoroquinolone-resistant E. coli strains were isolated in 10 (32%) patients in the second sample. In eight of these patients isolates were susceptible 3 months later. No patient developed infection due to fluorquinolone-resistant E. coli. No differences were observed in outcome between patients with susceptible and resistant flora.

Original languageEnglish (US)
Pages (from-to)117-120
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume44
Issue number1
DOIs
StatePublished - Aug 6 1999

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis'. Together they form a unique fingerprint.

  • Cite this

    Perea, S., Hidalgo, M., Arcediano, A., Ramos, M. J., Gomez, C., Hornedo, J., Lumbreras, C., Folgueira, D., Cortes-Funes, H., & Rodriguez-Noriega, A. (1999). Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. Journal of Antimicrobial Chemotherapy, 44(1), 117-120. https://doi.org/10.1093/jac/44.1.117